Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

Dutch firm reinvests in CETP inhibitor five years after return from Amgen deal

By Paul Bonanos, Associate Editor
August 25, 2020 9:46 PM UTC

Five years after reaping a strong return from cholesterol-lowering molecule obicetrapib, Forbion is again investing in the program based on a belief it can serve some dyslipidemia patients where others in its class fell short.

This time, the firm has created a start-up to reacquire the CETP inhibitor and take it through pivotal studies following Amgen’s decision to halt its development. A Phase III program is due to begin next year...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Dezima Pharma B.V.